These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 29382302

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R, CLICaP.
    Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
    [Abstract] [Full Text] [Related]

  • 23. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
    Wang Y, Li RQ, Ai YQ, Zhang J, Zhao PZ, Li YF, He WJ, Xia YX, Li WH.
    Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [Abstract] [Full Text] [Related]

  • 28. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M, Stordal B.
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [Abstract] [Full Text] [Related]

  • 29. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    Li MX, He H, Ruan ZH, Zhu YX, Li RQ, He X, Lan BH, Zhang ZM, Liu GD, Xiao HL, Wu Y, Zhu B, Wang G, Yang ZZ.
    BMC Cancer; 2017 Apr 04; 17(1):245. PubMed ID: 28376735
    [Abstract] [Full Text] [Related]

  • 32. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M, Spaggiari L, de Braud F, Barberis M.
    J Thorac Oncol; 2011 Nov 04; 6(11):1895-901. PubMed ID: 21841502
    [Abstract] [Full Text] [Related]

  • 33. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep 04; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 34. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 04; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 35. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM.
    Lung Cancer; 2017 Feb 04; 104():58-64. PubMed ID: 28213001
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
    Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL.
    Lung Cancer; 2014 Jul 04; 85(1):66-73. PubMed ID: 24780111
    [Abstract] [Full Text] [Related]

  • 37. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu C, Zhang X, Zhao N, Su J, Yang J, Yan H, Wu Y, Zhou Q.
    Oncotarget; 2017 Jan 17; 8(3):4994-5002. PubMed ID: 27999211
    [Abstract] [Full Text] [Related]

  • 38. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.
    J Natl Cancer Inst; 2017 Jun 01; 109(6):. PubMed ID: 28376144
    [Abstract] [Full Text] [Related]

  • 39. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
    Chen H, Yao W, Chu Q, Han R, Wang Y, Sun J, Wang D, Wang Y, Cao M, He Y.
    Cancer Lett; 2015 Dec 01; 369(1):97-102. PubMed ID: 26341687
    [Abstract] [Full Text] [Related]

  • 40. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar 01; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.